SEC Tracker
Get the app

Rigel Pharmaceuticals RIGL

Rigel Pharmaceuticals reports Q3 2026 financial results

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Third quarter 2026 total revenues of $80.9 million
  2. VEPPANU generated $6.6 million in net product sales
  3. Updated 2026 revenue outlook of $290 to $295 million

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Rigel Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Amarin AMRN public float $335M, Jun 30, 2025
  2. Usana Health Sciences USNA public float $328M, Jun 27, 2025
  3. Altimmune ALT public float $327M, Jun 30, 2025
  4. Prothena PRTA public float $327M, Jun 30, 2025
  5. Northwest Biotherapeutics NWBO public float $340M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.